Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.30 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16939404 | 0.81 | PNMT (0.34) | SLC6A2 | |
| SCHEMBL16939403 | 0.81 | P2RX7 (0.41) | P2RX7IDO1SLC6A2SLC6A4AKR1C3 | |
| SCHEMBL13990809 | 0.80 | LMNA (0.36) | PDE2AKLKB1IDO1AKR1C3AKR1C2 | |
| SCHEMBL23434803 | 0.78 | KDM4E (0.35) | SLC6A2LMNA | |
| SCHEMBL19443758 | 0.77 | P2RX7 (0.45) | P2RX7SLC6A2SLC6A4PYCR1 | |
| SCHEMBL21446974 | 0.77 | IDO1 (0.39) | KLKB1IDO1 | |
| SCHEMBL2922519 | 0.77 | IDO1 (0.35) | KLKB1IDO1 | |
| SCHEMBL20355248 | 0.74 | P2RX7 (0.43) | P2RX7IDO1SLC6A2SLC6A4LMNA | |
| SCHEMBL12263328 | 0.73 | P2RX7 (0.36) | PDE2AP2RX7IDO1AKR1C3AKR1C2 | |
| SCHEMBL14227249 | 0.71 | SLC6A2 (0.50) | P2RX7SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220047592-A1 | METHODS OF TREATING RESPIRATORY DISEASES USING C5a INHIBITORS | CHEMOCENTRYX, INC. | 2022-02-17 | — | — | US | disclosed |
| US-20210106568-A1 | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | CHEMOCENTRYX, INC. | 2021-04-15 | — | — | US | disclosed |
| US-20210052612-A1 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2021-02-25 | — | — | US | disclosed |
| US-10828285-B2 | Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors | CHEMOCENTRYX, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20190300526-A1 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2019-10-03 | — | — | US | disclosed |
| US-20190192491-A1 | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | CHEMOCENTRYX, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192491-A1 | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | C5AR1, C5AR2, C3AR1 | PDE2A 1045/4885KLKB1 782/4885P2RX7 124/4885 |
| US-20190300526-A1 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS | C5AR2, C5AR1, C3AR1 | PDE2A 1246/4885KLKB1 1422/4885P2RX7 96/4885 |
| US-10828285-B2 | Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors | C5AR1, C5AR2, C3AR1 | PDE2A 1045/4885KLKB1 782/4885P2RX7 124/4885 |
| US-20210052612-A1 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS | C5AR2, C5AR1, C3AR1 | PDE2A 1246/4885KLKB1 1422/4885P2RX7 96/4885 |
| US-20220047592-A1 | METHODS OF TREATING RESPIRATORY DISEASES USING C5a INHIBITORS | C3AR1, C5, C5AR1 | PDE2A 984/4885KLKB1 279/4885P2RX7 620/4885 |
| US-20210106568-A1 | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | C5AR1, C5AR2, C3AR1 | PDE2A 1045/4885KLKB1 782/4885P2RX7 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.